@entity1149 is one of the most common @entity5 worldwide. The majority of @entity1 are not treatable with curative intent because of the extent of disease or @entity1 comorbidity. Radiotherapy to the primary @entity5 is used with the aim of palliating troublesome local symptoms in approximately 25% of @entity1 . The dose/fractionation regimens used evolved empirically, and surveys have shown widespread variation. It has not yet been clearly established which regimens give the most benefit and least @entity137 . This systematic review identified 12 randomized controlled trials comparing palliative external beam radiotherapy regimens. Narrative synthesis has been performed. Palliative radiotherapy is effective in controlling symptoms. There is no strong evidence that better palliation is obtained with higher radiation doses but good evidence that @entity137 is greater. There is evidence of a modest survival benefit with higher dose schedules in @entity1 with good performance status. The majority of @entity1 should receive short courses (one or two fractions) of hypofractionated radiotherapy, Selected @entity1 with good performance status should be considered for higher dose regimens if the chance of modest improvement in survival and palliation is considered worth the additional inconvenience and @entity137 .

Palliative thoracic radiotherapy for XXXX : a systematic review.

@entity5 :: ('MESH:D009369', 'Disease') :: ['intrathoracic tumor', 'malignant tumors'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['Non-small-cell lung cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung cancer']
